Atlas Arteria Ltd
ALX: XASX (AUS)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
A$2.70 | Lzjnrc | Pzvmqpgh |
Reducing Atlas Arteria's FVE 3% on Lingering Coronavirus Impacts
We trim our fair value estimate for narrow moat rated Atlas Arteria by 3% to AUD 6.00 after downgrading earnings forecasts because of continuing impacts from the coronavirus pandemic. We now forecast EBITDA grows at a compound annual rate of 7.1% over the next five years, compared with 7.9% previously. The stock appears fairly valued at current prices, offering a forecast 2021 yield of 4.6%.